Researchers from Indiana University School of Medicine had a large presence and leadership role at the 2023 Alzheimer's Association International Conference in Amsterdam, Netherlands, with involvement in more than 150 presentations at the four-day meeting. The annual conference is the largest and most influential international meeting dedicated to advancing dementia science.
As the primary medical specialty that provides care to people with Alzheimer’s disease, the American Academy of Neurology has been invited to testify on Capitol Hill before members of the United States House of Representatives on new drugs for Alzheimer’s disease.
Pitt received $1 million to support four projects that advance new and ongoing translational research on aging. These studies have the potential to create novel products and technologies to improve health outcomes and reduce the burden of age-related problems.
A recent study from the lab of the University of Kentucky’s Sanders-Brown Center on Aging Director Linda Van Eldik, Ph.D., has been published in PLOS ONE. The work centers around the idea that various anti-inflammatory drugs could be effective treatments for Alzheimer’s disease (AD). This study focused on a protein known as p38.
Press materials are now available for NUTRITION 2023, the annual flagship meeting of the American Society for Nutrition (ASN).
The neurons in our bodies are dotted with tiny pores that let essential molecules pass in and out of our cells. Neurons need these channels to send the signals that allow us to move, think, and perceive the world around us. Now, structural biologists at Cold Spring Harbor Laboratory (CSHL) have captured never-before-seen images of one of the largest pores in human neurons.
Study represents a major milestone toward health equity for underrepresented populations in Alzheimer’s disease research
Researchers at Washington University School of Medicine in St. Louis and Lund University in Sweden have discovered an Alzheimer's biomarker in the cerebrospinal fluid known as MTBR-tau243 can be used to track the progression of disease and could speed drug development.
Because amyloidosis doesn’t affect a specific organ and can be present throughout the body including the heart, kidneys, liver and brain, unraveling the underlying cause of amyloid fibril creation – a hallmark of this disease – is complex and challenging. A monumental $11.5 million gift from philanthropists Ann and John Wood will enable FAU’s Schmidt College of Medicine to create a game-changing infrastructure using a whole-body approach and multi-disciplinary team.
Older people who have little social contact with others may be more likely to have loss of overall brain volume, and in areas of the brain affected by dementia, than people with more frequent social contact, according to a study published in the July 12, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology.
That experiences leave their trace in the connectivity of the brain has been known for a while, but a pioneering study by researchers at DZNE and TUD Dresden University of Technology now shows how massive these effects really are.
The molecular processes responsible for natural ageing of cells are poorly understood. Studying conditions in humans where ageing is accelerated due to genetic causes presents opportunities to learn about the mechanisms that control ageing and devise strategies to slow down the ageing process.
What makes the vital layer of protective cells around the brain and spinal cord — the blood-brain barrier — more or less permeable has been one of the more mystifying questions in neuroscience.
A simple but revolutionary test to improve early detection for dementia and Alzheimer’s disease could soon be helping patients and their families, thanks to a significant £1.5 million funding boost awarded to the universities of Bath and Bristol.
On July 6, 2023, the U.S. Food and Drug Administration (FDA) granted full approval to lecanemab, marketed as Leqembi, for the treatment of Alzheimer’s disease. The University of Kentucky’s Sanders-Brown Center on Aging has been working with this drug and others like it for more than a decade.
A $40.5 million grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), will fund the Asian Cohort for Alzheimer’s Disease (ACAD) study at Penn Medicine and 15 other academic research centers across the United States and Canada.
Age-related cognitive decline and the escalating prevalence of Alzheimer’s disease are pressing social challenges as the population of those 65 and older continues to expand. Age is the primary risk factor, but research has shown that social and structural determinants of health play significant roles in the higher incidence of Alzheimer’s among marginalized communities.
Hackensack Meridian Health Physicians react to FDA approval of Alzheimer's drug lecanemab/ Leqembi. Available to discuss its uses, side effects and instances when they have prescribed it.
Regular physical activity may protect against cognitive decline as we get older, but this protective effect may be diminished for people who are not getting enough sleep, according to a new study by UCL researchers.
Older people who have fluctuating levels of cholesterol and triglycerides may have a higher risk of Alzheimer’s disease and related dementias compared to people who have steady levels, according to new research published in the July 5, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology. While the study found a link, it does not prove that fluctuating levels of cholesterol and triglycerides cause dementia.
Taking good care of your teeth may be linked to better brain health, according to a study published in the July 5, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study found that gum disease and tooth loss were linked to brain shrinkage in the hippocampus, which plays a role in memory and Alzheimer’s disease. The study does not prove that gum disease or tooth loss causes Alzheimer’s disease; it only shows an association.
Older adults with Alzheimer disease and related dementia who were admitted to an ICU were much less likely to be discharged home and faced almost twice the risk of dying soon after discharge and within the 12 months afterward.
Protein aggregates accumulate during aging and are linked to neurodegenerative diseases like Alzheimer’s, Parkinson’s or Huntington’s disease.
Cedars-Sinai patient care teams are preparing to offer lecanemab, a new Alzheimer’s disease treatment expected to soon receive approval from the U.S. Food and Drug Administration (FDA), to patients in the coming months.
Mild cognitive impairment, which occurs in about one in six individuals in the U.S., age 65 and older, remains substantially underdiagnosed, especially in disadvantaged populations.
The June 2023 issue of SLAS Discovery contains one review article, five full-length articles and two technical briefs covering spheroid models, 3D cell high-throughput screening (HTS) applications for treating Alzheimer’s and other drug discovery research.
A new AI tool that could help doctors assess the early signs of dementia and Alzheimer’s more quickly and efficiently, has been developed by researchers at the University of Sheffield.
Dogs who slow down physically also slow down mentally, according to a new study from North Carolina State University. Measuring gait speed in senior dogs could be a simple way to monitor their health and to document decline in their neurological function as they age.
In a study that followed more than 2,000 community-dwelling older adults over eight years, researchers at Johns Hopkins Medicine say they have significant new evidence of a link between decreased sense of smell and risk of developing late-life depression.
Women with atrial fibrillation progress more rapidly to cognitive impairment and dementia than men with the heart rhythm condition, according to research presented today at ACNAP 2023, a scientific congress of the European Society of Cardiology (ESC)1 and published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
Alzheimer's disease (AD) mainly affects the older population. Recent research found early disease signs in cell culture models of early human brain development, raising the possibility that the disease has its origins much earlier in life, possibly during embryogenesis – the formation and development of an embryo.
In an eight-year study of more than 600 community-dwelling older adults, Johns Hopkins Medicine researchers say they have further linked levels of cell-free DNA (DNA fragments resulting from cell death) circulating in the blood to chronic inflammation and frailty.
Today, Veravas, a leading innovator in clinical diagnostics, announced the launch of its groundbreaking VeraBIND™ (Biomarker Isolation and N-richment for Detection) technology
Adults who live in walkable neighborhoods are more likely to socialize and have a stronger sense of community, report researchers at the UC San Diego Herbert Wertheim School of Public Health and Human Longevity Science.
New research from Boston Medical Center found a significant correlation between biomarkers in the vitreous humor of the eye and pathologically confirmed cases of Alzheimer’s disease (AD) and Chronic Traumatic Encephalopathy (CTE) in post-mortem brain and eye tissue.
Scientists at City of Hope have developed universal donor stem cells that could one day provide lifesaving therapy to children with lethal brain conditions, such as Canavan disease, as well as to people with other degenerative diseases, such as Alzheimer’s and multiple sclerosis.
The University of California, Irvine has received a five-year, $10 million grant from the National Institutes of Health to lead a multi-institutional study of specific brain cell vulnerabilities to abnormal tau protein deposits in regions affected in the early stages of Alzheimer’s disease.
Alzheimer’s disease causes changes to the brain that begin two decades or more before symptoms appear. A study by researchers at Washington University School of Medicine in St. Louis reveals that the bacteria that live in the gut also change before Alzheimer’s symptoms arise, a discovery that could lead to diagnostics or treatments for Alzheimer’s disease that target the gut microbiome.
A new approach could enhance memory and learning in individuals with Down syndrome by stabilizing a key component in the body's protein sorting system called the retromer complex.
The American Academy of Neurology (AAN), the world’s largest association of neurologists and neuroscience professionals, has submitted a Formal National Coverage Determination (NCD) Reconsideration Request to the Centers for Medicare & Medicaid Services (CMS) regarding the existing national coverage determination on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease, including the new therapy lecanemab.
Researchers from The University of Texas at El Paso’s School of Pharmacy will explore the viability of a new treatment for vascular dementia, thanks to a $2.2 million grant from the National Institutes of Health National Institute of Neurological Disorders and Stroke.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
